A smaller player in the race to a COVID-19 vaccine, Arcturus (ARCT) – Get Report, is in the middle of trials for its vaccine candidate.
On Nov. 9, it released earnings and updates on its candidate.
“This has been an exciting period for Arcturus highlighted by our preliminary ARCT-021 Phase 1/2 COVID-19 vaccine study results. These data, as well as those from our ARCT-810 Phase 1 study, illustrate a highly productive period of clinical advancement of our novel mRNA based therapeutic candidates. The ARCT-021 Phase 1/2 data provide clinical validation for our unique vaccine candidate and suggest that our self-replicating mRNA-based investigational vaccine could have a differentiated clinical profile and may allow vaccination at low doses. We believe that ARCT-021 could play an important role in the massive global vaccination campaigns that will be necessary to control the COVID-19 pandemic. We look forward to rapidly moving ARCT-021 forward in later-stage clinical studies,” said Joe Payne, CEO of Arcturus.
Payne joined TheStreet to talk about the company’s vaccine candidate and why the company is pursuing a candidate that will come in powdered form and therefore won’t need to be frozen like other vaccine candidates from companies such as Moderna (MRNA) – Get Report or Pfizer (PFE) – Get Report.
Read more from Katherine Ross here.